Actively Recruiting
Open-label Phase I Study Evaluating Safety and Activity of 225Ac-ETN029 in Adults With Advanced DLL3-positive Solid Tumors
Led by Novartis Pharmaceuticals · Updated on 2026-09-22
116
Participants Needed
8
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
Researchers are studying the safety, tolerability, dosimetry, pharmacokinetics, pharmacodynamics, and preliminary effectiveness of a new radioligand therapy called 225Ac-ETN029 in adults aged 18 and older who have advanced DLL3-expressing solid tumors. This phase I trial includes patients with various advanced neuroendocrine cancers such as small cell lung carcinoma, large cell neuroendocrine carcinoma, and other related cancers. The study also evaluates the safety and imaging features of 111In-ETN029. Participants receive the 225Ac-ETN029 treatment, and some also receive 111In-ETN029 for imaging purposes. The trial has two parts a dose escalation phase to determine safe and appropriate doses, followed by a dose expansion phase to further assess safety and early anti-tumor effects. The imaging agent 111In-ETN029 is used to study tumor uptake and distribution. During the study, participants undergo multiple assessments including safety monitoring for adverse events and dose limiting toxicities, blood tests to measure drug levels and clearance, imaging scans to evaluate tumor response, and tracking of disease progression and response duration. Follow-up visits continue for up to 36 months to assess long-term safety and treatment effects. Participants may be monitored for up to approximately 42 months in total.
CONDITIONS
Brief Title
Phase I Study of [225Ac]Ac-ETN029 in Patients With Advanced DLL3-expressing Solid Tumors
Research Team
N
Novartis Pharmaceuticals
N
Novartis Pharmaceuticals
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here